🚀 VC round data is live in beta, check it out!
Snibe Valuation Multiples
Discover revenue and EBITDA valuation multiples for Snibe and similar public comparables like Ypsomed, APT Medical, Andon Health, Imeik Technology Development and more.
Snibe Overview
About Snibe
Shenzhen New Industries Biomedical Engineering Co Ltd is researching, developing, producing, and selling a series of fully automatic chemiluminescence immunoassay instruments and supporting reagents.
Founded
1995
HQ
Employees
2.8K
Website
Financials (LTM)
EV
$5B
Snibe Financials
Snibe reported last 12-month revenue of $713M and EBITDA of $309M.
In the same LTM period, Snibe generated $492M in gross profit, $309M in EBITDA, and $257M in net income.
Revenue (LTM)
Snibe P&L
In the most recent fiscal year, Snibe reported revenue of $665M and EBITDA of $334M.
Snibe expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $713M | XXX | $665M | XXX | XXX | XXX |
| Gross Profit | $492M | XXX | $479M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 72% | XXX | XXX | XXX |
| EBITDA | $309M | XXX | $334M | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | 50% | XXX | XXX | XXX |
| EBIT Margin | 40% | XXX | 44% | XXX | XXX | XXX |
| Net Profit | $257M | XXX | $268M | XXX | XXX | XXX |
| Net Margin | 36% | XXX | 40% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Snibe Stock Performance
Snibe has current market cap of $5B, and enterprise value of $5B.
Market Cap Evolution
Snibe's stock price is $6.66.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $5B | 0.0% | XXX | XXX | XXX | $0.34 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSnibe Valuation Multiples
Snibe trades at 6.9x EV/Revenue multiple, and 15.9x EV/EBITDA.
EV / Revenue (LTM)
Snibe Financial Valuation Multiples
As of April 20, 2026, Snibe has market cap of $5B and EV of $5B.
Equity research analysts estimate Snibe's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Snibe has a P/E ratio of 20.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV/Revenue | 6.9x | XXX | 7.4x | XXX | XXX | XXX |
| EV/EBITDA | 15.9x | XXX | 14.7x | XXX | XXX | XXX |
| EV/EBIT | 17.3x | XXX | 16.8x | XXX | XXX | XXX |
| EV/Gross Profit | 10.0x | XXX | 10.2x | XXX | XXX | XXX |
| P/E | 20.4x | XXX | 19.5x | XXX | XXX | XXX |
| EV/FCF | 22.6x | XXX | 34.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Snibe Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Snibe Margins & Growth Rates
Snibe's revenue in the last 12 month grew by 15%.
Snibe's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Snibe's rule of 40 is 59% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Snibe's rule of X is 81% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Snibe Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | 50% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | (12%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 59% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 81% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 17% | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11% | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Snibe Public Comps
See public comps and valuation multiples for other Laboratory Services and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Snibe | XXX | XXX | XXX | XXX | XXX | XXX |
| Ypsomed | XXX | XXX | XXX | XXX | XXX | XXX |
| APT Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Andon Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Imeik Technology Development | XXX | XXX | XXX | XXX | XXX | XXX |
| Mirion | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Snibe M&A Activity
Snibe acquired XXX companies to date.
Last acquisition by Snibe was on XXXXXXXX, XXXXX. Snibe acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Snibe
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSnibe Investment Activity
Snibe invested in XXX companies to date.
Snibe made its latest investment on XXXXXXXX, XXXXX. Snibe invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Snibe
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Snibe
| When was Snibe founded? | Snibe was founded in 1995. |
| Where is Snibe headquartered? | Snibe is headquartered in China. |
| How many employees does Snibe have? | As of today, Snibe has over 2K employees. |
| Is Snibe publicly listed? | Yes, Snibe is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Snibe? | Snibe trades under 300832 ticker. |
| When did Snibe go public? | Snibe went public in 2020. |
| Who are competitors of Snibe? | Snibe main competitors are Ypsomed, APT Medical, Andon Health, Imeik Technology Development. |
| What is the current market cap of Snibe? | Snibe's current market cap is $5B. |
| What is the current revenue of Snibe? | Snibe's last 12 months revenue is $713M. |
| What is the current revenue growth of Snibe? | Snibe revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Snibe? | Current revenue multiple of Snibe is 6.9x. |
| Is Snibe profitable? | Yes, Snibe is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Snibe? | Snibe's last 12 months EBITDA is $309M. |
| What is Snibe's EBITDA margin? | Snibe's last 12 months EBITDA margin is 43%. |
| What is the current EV/EBITDA multiple of Snibe? | Current EBITDA multiple of Snibe is 15.9x. |
| What is the current FCF of Snibe? | Snibe's last 12 months FCF is $217M. |
| What is Snibe's FCF margin? | Snibe's last 12 months FCF margin is 30%. |
| What is the current EV/FCF multiple of Snibe? | Current FCF multiple of Snibe is 22.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.